{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.8","upperLimit":"46.7","value":"40.7"},{"groupId":"OG001","lowerLimit":"16.6","upperLimit":"31.3","value":"23.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"description":"Defined as achieving a best overall response of confirmed complete response (CR) or confirmed partial response (PR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"NUMBER","populationDescription":"ITT - PFS population, subset of participants with measurable disease by BICR at baseline. The ITT-PFS Population includes the first 480 randomized participants in the ITT analysis population (evaluated by their randomized treatment assignment).","reportingStatus":"POSTED","timeFrame":"34.6 months","title":"Confirmed Objective Response Rate (ORR) Per RECIST 1.1 as Determined by BICR","type":"SECONDARY","unitOfMeasure":"percentage of participants"}